USOR 24266 - Ph3 Study of Sonrotoclax plus Anti-CD20 in patients with chronic/small Lymphocytic Leukemia/Lymph

A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Disease Types: Leukemia, Lymphoma

Available at: Arlington Heights, Niles